RE:Follow the money, a generic form of Epidiolex facing subaru1i wrote: lengthy court battles in litigation or the application of cannabinoid API's in the field of oncology? How many companies did JAZZ name in their lawsuits....around 4 or so if not more? Those companies going after generic Epidiolex....that many companies and the generic price of Epidiolex comes crashing down as do profit margins with that many players in that arena. The money rests in EXCLUSIVTIVITY....coming out with a NEW drug with a much larger target population and protected by patents on everything from the plant strain, extraction processing, and final consumer pharmaceutical product.
I think all this talk about a generic Epidiolex is what they call a "red herring" and not the real money maker in pharmaceutical cannbinoid API's.
So you run a company like LABS and would your strategy be to go first after a generic form facing legal battles and falling prices with a generic or would you set your strategy on something that is completely newl and effective to treat cancers?
So like I said, follow the money and imho, the money shot is being tightly held as a secret for "competitive reasons" where a generic form of Epidiolex does not fit the wording expressed by the CEO.
Something else is brewing and it could be within the scope of their NDA, new drug application and not imho, a generic form of Epidiolex.
i dont think LABS is nessecarily looking to get their bown drug approved all we need is for a few pharma companies to get FDA,HC,Brazil etc. aprovals for any drug using Pharma grade CBD,CBN etc. and Labs has a great chance of supplying any and all of these companies with the API
More companies need to get approval and we are in the money
If LABS launches their own parma product and gets it vaproved that would just be gravie on the gravie